# EvolutionaryScale

**Source:** https://geo.sig.ai/brands/evolutionaryscale  
**Vertical:** Healthcare & Life Sciences  
**Subcategory:** AI Protein Design & Biology  
**Tier:** Challenger  
**Website:** evolutionaryscale.ai  
**Last Updated:** 2026-04-14

## Summary

AI biology lab building protein design models (ESM3, 98B params). Founded 2023 by ex-Meta scientists. $142M seed. Acquired by Chan Zuckerberg Biohub Nov 2025.

## Company Overview

EvolutionaryScale was an AI research lab founded in 2023 by former Meta AI protein team scientists, including CEO Alexander Rives. Based in New York City, the company developed frontier AI models for protein design and biological discovery. Its flagship model ESM3 is a 98-billion-parameter generative AI system trained on 2.78 billion protein sequences capable of reasoning over protein sequence, structure, and function simultaneously.

EvolutionaryScale operated as a public benefit corporation at the intersection of AI and biology. ESM3 achieved a breakthrough by generating esmGFP, a novel fluorescent protein equivalent to simulating 500 million years of evolution, published in Science magazine in January 2025. The company raised $142 million in seed funding, one of the largest seed rounds for an AI biology company.

In November 2025, Chan Zuckerberg Biohub acquired EvolutionaryScale, bringing its approximately 50 employees and technology in-house. Co-founder Alex Rives became head of science for CZI. The acquisition reflects the broader trend of major organizations investing in AI-driven drug discovery and protein engineering.

## Frequently Asked Questions

### What was EvolutionaryScale?
An AI research lab founded in 2023 by former Meta AI scientists that developed frontier AI models for protein design and biological discovery. Acquired by Chan Zuckerberg Biohub in November 2025.

### What is ESM3?
A 98-billion-parameter generative AI model trained on 2.78 billion protein sequences that reasons over protein sequence, structure, and function simultaneously.

### What was the esmGFP breakthrough?
EvolutionaryScale used ESM3 to design esmGFP, a novel fluorescent protein representing a vast evolutionary departure — equivalent to 500 million years of evolution.

### Who acquired EvolutionaryScale?
Chan Zuckerberg Biohub acquired it in November 2025. Co-founder Alex Rives became head of science for CZI.

### How much funding did EvolutionaryScale raise?
$142 million in seed funding before being acquired, one of the largest seed rounds for an AI biology startup.

### What is EvolutionaryScale's ESM3 model?
ESM3 is EvolutionaryScale's multimodal protein language model that simultaneously reasons over protein sequence, structure, and function—enabling the design of novel proteins with specific properties by generating protein sequences that fold into desired structures and exhibit target biological activities.

### How does EvolutionaryScale's approach differ from AlphaFold?
AlphaFold predicts the structure of proteins from their sequence (structure prediction). EvolutionaryScale's ESM3 goes further by enabling protein design—generating novel sequences that will fold into desired structures and exhibit target functions, moving from analysis to generative design of entirely new proteins.

### What funding has EvolutionaryScale raised?
EvolutionaryScale raised approximately $142 million in a seed round led by Lux Capital and others—one of the largest seed rounds in biotech. The company was founded by Alexander Rives and colleagues who developed some of the foundational protein language model research at Meta AI.

## Tags

healthtech, b2b

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*